BDO has provided buy-side CDD and strategic advice to Mérieux Equity Partners, regarding its investment in Curea Medical GmbH, a key player in the German advanced wound care market.

Curea benefits from its proprietary SuperCore® superabsorbent technology, allowing it to successfully compete with larger market players in high-to-medium exudate wound management.

The BDO CDD team delivered key strategic insights to Mérieux regarding Curea's market positioning in the German advanced wound care market and its growth potential in domestic & international markets.

 

“We were delighted to work with BDO as part of our commercial due diligence for the acquisition of a majority stake in Curea Medical. Their support was extremely valuable in helping us gain a clear understanding of the superabsorbent dressings market, its key drivers, and its structure. Thanks to their work, we were able to strengthen our conviction regarding Curea’s distinctive positioning in the German market and its ability to expand into certain geographies. We particularly appreciated the quality of their analysis and their responsiveness, and we would be pleased to work with BDO again on future projects.”
Investment Manager, Mérieux Equity Partners

The BDO project team included:
CDD: Gurpal Ahluwalia, David Wentholt, Sam Harraden, Charlotte Colle, Andrew Goodluck, Charles Jervis, Sarah Postlethwaite, James Cook